Key Developments: Baxter International Inc (BAX.N)

BAX.N on New York Stock Exchange

75.30USD
10:50am EDT
Price Change (% chg)

$-0.23 (-0.30%)
Prev Close
$75.53
Open
$75.53
Day's High
$75.64
Day's Low
$75.02
Volume
81,458
Avg. Vol
552,380
52-wk High
$77.30
52-wk Low
$62.80

Search Stocks

Latest Key Developments (Source: Significant Developments)

Baxter International Inc announces positive top-line results from Its phase 3 study of BAX 855, extended half-life recombinant FVIII for hemophilia a patients
Thursday, 21 Aug 2014 09:00am EDT 

Baxter International Inc:Announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].Met its primary endpoint in reducing annualized bleed rates (ABR) in the prophylaxis arm compared to the on-demand arm.Top-line results from the prospective, global, multi-center Phase 3 study demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older.Patients in a twice-weekly prophylaxis arm experienced a 95 percent reduction in median ABR as compared to those in the on-demand arm.BAX 855 was also effective in treating bleeding episodes, 96 percent of which were controlled with one or two infusions.  Full Article

FDA advisory committee panel provides favorable recommendation on Baxter International Inc's HyQvia for primary immunodeficiency
Thursday, 31 Jul 2014 01:55pm EDT 

Baxter International Inc and Halozyme Therapeutics, Inc:Says Blood Products Advisory Committee (BPAC) of U.S. Food and Drug Administration (FDA) voted 15-1 that HyQvia [Immune Globulin Infusion 10 pct (Human) with Recombinant Human Hyaluronidase].Says Baxter's investigational subcutaneous treatment for patients with primary immunodeficiency (PI), has favorable risk/benefit profile.  Full Article

Baxter International Inc announces divestiture of commercial vaccines business to Pfizer Inc
Wednesday, 30 Jul 2014 08:02am EDT 

Baxter International Inc:Entered into a definitive agreement to sell its two commercially marketed vaccines and related production facilities to Pfizer Inc.For a total cash consideration of $635 million, subject to certain adjustments.  Full Article

Baxter International Inc declares quarterly dividend
Tuesday, 22 Jul 2014 09:00am EDT 

Baxter International Inc:Declares a quarterly dividend of $0.52 per share.Payable on Oct. 1 to shareholders of record as of Sept. 5.  Full Article

Baxter International Inc gives Q3 2014 outlook in line with analysts' estimates; raises FY 2014 outlook
Thursday, 17 Jul 2014 07:00am EDT 

Baxter International Inc:Expects Q3 2014 sales growth of about 12 to 13 percent, excluding the impact of foreign currency.Expects Q3 2014 earnings, before special items, of $1.28 to $1.32 per diluted share.Q3 2014 revenues of $4.12 bln and EPS of $1.32 - Thomson Reuters I/B/E/S.Expects FY 2014 sales growth of 10 to 11 percent, before the impact of foreign exchange.Expects FY 2014 earnings, before special items, of $5.10 to $5.20 per diluted share.The FY 2014 earnings guidance excludes the $0.62 per diluted share of special items comprising $0.49 per diluted share of items recorded in the first half of the year, and projected intangible asset amortization expense of $0.13 per diluted share for the remainder of the year.FY 2014 revenues of $16.63 bln and EPS of $5.15 - Thomson Reuters I/B/E/S.  Full Article

Baxter International Inc Names chief financial officers for new biopharmaceutical spin-off and Baxter International Inc
Monday, 7 Jul 2014 09:00am EDT 

Baxter International Inc:Says Robert J. Hombach, currently chief financial officer for Baxter International Inc., will be appointed chief financial officer and will assume additional operational responsibilities for the independent biopharmaceuticals company.James K. Saccaro will rejoin Baxter Aug. 4, and will assume the role of chief financial officer of Baxter International Inc., reporting to Robert L. Parkinson.  Full Article

Baxter International raises quarterly dividend
Monday, 5 May 2014 04:30pm EDT 

Baxter International Inc:Declares quarterly dividend of $0.52 per Baxter common share, representing a 6 pct increase.Payable on July 1 to shareholders of record as of June 6.  Full Article

Baxter International announces FDA approval of ADVATE with BAXJECT III reconstitution system
Wednesday, 23 Apr 2014 09:00am EDT 

Baxter International Inc:Says the U.S. Food and Drug Administration (FDA) has approved a new reconstitution system for ADVATE (Antihemophilic Factor [Recombinant]).ADVATE and the diluent come pre-packaged in the new BAXJECT III reconstitution system.Reconstitution system was developed to reduce the number of steps in reconstitution process for hemophilia A patients and caregivers, compared to the previous process with the BAXJECT II needle-less transfer device.  Full Article

Baxter International Inc gives Q2 2014 revenue outlook above analysts' estimates, Q2 2014 EPS outlook below analysts' estimates; reaffirms FY 2014 outlook
Thursday, 17 Apr 2014 07:00am EDT 

Baxter International Inc:Expects Q2 2014 sales growth of about 12 to 13 percent, excluding the impact of foreign currency.Expects Q2 2014 earnings, before special items, of $1.18 to $1.22 per diluted share.Q2 2014 earnings guidance excludes about $0.07 per diluted share of projected intangible asset amortization expense.The company reported revenue of $3.95 bln in Q1 2014.Q2 2014 revenues of $4.17 bln and EPS of $1.33 - Thomson Reuters I/B/E/S.Expects FY 2014 sales growth of 9 to 10 percent, before the impact of foreign exchange.FY 2014 earnings, before special items, of $5.05 to $5.25 per diluted share.FY 2014 earnings guidance excludes $0.38 per diluted share of special items comprising $0.18 per diluted share of items recorded in the Q1, and projected intangible asset amortization expense of $0.20 per diluted share for the remainder of the year.FY 2014 revenues of $16.60 bln and EPS of $5.13 - Thomson Reuters I/B/E/S.  Full Article

Baxter International invests to construct facility of $1 billion
Thursday, 17 Apr 2014 06:15am EDT 

Baxter International Inc:Decides to invest $1bln to construct a 1 mln-square-foot plasma fractionation facility with purification and fill/finish suites in Covington, Georgia.In support of the massive project, now under construction, the state is building the $14 mln Georgia BioScience Training Center adjacent to the new plant.  Full Article

Long-acting version of Baxter's hemophilia drug succeeds in study

- Baxter International Inc said a more potent version of its flagship blood disorder drug Advate met the main goal in a late-stage study.

Search Stocks